|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net revenues | |||||
| Product | |||||
| Other | |||||
| Total net revenues | |||||
| Costs and expenses: | |||||
| Cost of products sold | |||||
| Selling and marketing | |||||
| Research and development | |||||
| General and administrative | |||||
| Amortization and impairment | |||||
| Total costs and expenses | |||||
| Operating loss | |||||
| Interest income | |||||
| Other income | |||||
| Other income - settlement | |||||
| Other income - gain on insurance proceeds | |||||
| Interest expense | |||||
| Loss before income taxes | |||||
| Income tax (expense) benefit | |||||
| Net income (loss) from continuing operations | |||||
| Equity in loss of investee | |||||
| Net loss | |||||
| Net (income) loss at subsidiary attributable to noncontrolling interests | |||||
| Net loss attributable to common shareholders | |||||
| Loss per share attributable to common shareholders: | |||||
| -Continuing operations-basic | |||||
| Basic (in USD per share) | |||||
| Diluted (in USD per share) | |||||
| Weighted-average shares outstanding | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...